Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Minh V Huynh, Craig M Goodwin, Feifei Zhang, J Nathaniel Diehl, Mariaelena Pierobon, Elisa Baldelli, Sehrish Javaid, Karson Guthrie, Naim U Rashid, Emanuel F Petricoin, Adrienne D Cox, William C Hahn, Andrew J Aguirre, Adam J Bass, Channing J Der
{"title":"RHOAL57V通过IGF1R-PAK1-YAP1信号传导驱动弥漫性胃癌的发展。","authors":"Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Minh V Huynh, Craig M Goodwin, Feifei Zhang, J Nathaniel Diehl, Mariaelena Pierobon, Elisa Baldelli, Sehrish Javaid, Karson Guthrie, Naim U Rashid, Emanuel F Petricoin, Adrienne D Cox, William C Hahn, Andrew J Aguirre, Adam J Bass, Channing J Der","doi":"10.1126/scisignal.adg5289","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at different locations from the mutational hotspots in the structurally and biochemically related RAS. Tyr<sup>42</sup>-to-Cys (Y42C) and Leu<sup>57</sup>-to-Val (L57V) substitutions are the two most prevalent RHOA mutations in diffuse gastric cancer (DGC). RHOA<sup>Y42C</sup> exhibits a gain-of-function phenotype and is an oncogenic driver in DGC. Here, we determined how RHOA<sup>L57V</sup> promotes DGC growth. In mouse gastric organoids with deletion of <i>Cdh1</i>, which encodes the cell adhesion protein E-cadherin, the expression of RHOA<sup>L57V</sup>, but not of wild-type RHOA, induced an abnormal morphology similar to that of patient-derived DGC organoids. RHOA<sup>L57V</sup> also exhibited a gain-of-function phenotype and promoted F-actin stress fiber formation and cell migration. RHOA<sup>L57V</sup> retained interaction with effectors but exhibited impaired RHOA-intrinsic and GAP-catalyzed GTP hydrolysis, which favored formation of the active GTP-bound state. Introduction of missense mutations at KRAS residues analogous to Tyr<sup>42</sup> and Leu<sup>57</sup> in RHOA did not activate KRAS oncogenic potential, indicating distinct functional effects in otherwise highly related GTPases. Both RHOA mutants stimulated the transcriptional co-activator YAP1 through actin dynamics to promote DGC progression; however, RHOA<sup>L57V</sup> additionally did so by activating the kinases IGF1R and PAK1, distinct from the FAK-mediated mechanism induced by RHOA<sup>Y42C</sup>. Our results reveal that RHOA<sup>L57V</sup> and RHOA<sup>Y42C</sup> drive the development of DGC through distinct biochemical and signaling mechanisms.</p>","PeriodicalId":49560,"journal":{"name":"Science Signaling","volume":null,"pages":null},"PeriodicalIF":7.3000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791543/pdf/","citationCount":"0","resultStr":"{\"title\":\"RHOA<sup>L57V</sup> drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.\",\"authors\":\"Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, Minh V Huynh, Craig M Goodwin, Feifei Zhang, J Nathaniel Diehl, Mariaelena Pierobon, Elisa Baldelli, Sehrish Javaid, Karson Guthrie, Naim U Rashid, Emanuel F Petricoin, Adrienne D Cox, William C Hahn, Andrew J Aguirre, Adam J Bass, Channing J Der\",\"doi\":\"10.1126/scisignal.adg5289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at different locations from the mutational hotspots in the structurally and biochemically related RAS. Tyr<sup>42</sup>-to-Cys (Y42C) and Leu<sup>57</sup>-to-Val (L57V) substitutions are the two most prevalent RHOA mutations in diffuse gastric cancer (DGC). RHOA<sup>Y42C</sup> exhibits a gain-of-function phenotype and is an oncogenic driver in DGC. Here, we determined how RHOA<sup>L57V</sup> promotes DGC growth. In mouse gastric organoids with deletion of <i>Cdh1</i>, which encodes the cell adhesion protein E-cadherin, the expression of RHOA<sup>L57V</sup>, but not of wild-type RHOA, induced an abnormal morphology similar to that of patient-derived DGC organoids. RHOA<sup>L57V</sup> also exhibited a gain-of-function phenotype and promoted F-actin stress fiber formation and cell migration. RHOA<sup>L57V</sup> retained interaction with effectors but exhibited impaired RHOA-intrinsic and GAP-catalyzed GTP hydrolysis, which favored formation of the active GTP-bound state. Introduction of missense mutations at KRAS residues analogous to Tyr<sup>42</sup> and Leu<sup>57</sup> in RHOA did not activate KRAS oncogenic potential, indicating distinct functional effects in otherwise highly related GTPases. Both RHOA mutants stimulated the transcriptional co-activator YAP1 through actin dynamics to promote DGC progression; however, RHOA<sup>L57V</sup> additionally did so by activating the kinases IGF1R and PAK1, distinct from the FAK-mediated mechanism induced by RHOA<sup>Y42C</sup>. Our results reveal that RHOA<sup>L57V</sup> and RHOA<sup>Y42C</sup> drive the development of DGC through distinct biochemical and signaling mechanisms.</p>\",\"PeriodicalId\":49560,\"journal\":{\"name\":\"Science Signaling\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2023-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791543/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Signaling\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1126/scisignal.adg5289\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1126/scisignal.adg5289","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.
Cancer-associated mutations in the guanosine triphosphatase (GTPase) RHOA are found at different locations from the mutational hotspots in the structurally and biochemically related RAS. Tyr42-to-Cys (Y42C) and Leu57-to-Val (L57V) substitutions are the two most prevalent RHOA mutations in diffuse gastric cancer (DGC). RHOAY42C exhibits a gain-of-function phenotype and is an oncogenic driver in DGC. Here, we determined how RHOAL57V promotes DGC growth. In mouse gastric organoids with deletion of Cdh1, which encodes the cell adhesion protein E-cadherin, the expression of RHOAL57V, but not of wild-type RHOA, induced an abnormal morphology similar to that of patient-derived DGC organoids. RHOAL57V also exhibited a gain-of-function phenotype and promoted F-actin stress fiber formation and cell migration. RHOAL57V retained interaction with effectors but exhibited impaired RHOA-intrinsic and GAP-catalyzed GTP hydrolysis, which favored formation of the active GTP-bound state. Introduction of missense mutations at KRAS residues analogous to Tyr42 and Leu57 in RHOA did not activate KRAS oncogenic potential, indicating distinct functional effects in otherwise highly related GTPases. Both RHOA mutants stimulated the transcriptional co-activator YAP1 through actin dynamics to promote DGC progression; however, RHOAL57V additionally did so by activating the kinases IGF1R and PAK1, distinct from the FAK-mediated mechanism induced by RHOAY42C. Our results reveal that RHOAL57V and RHOAY42C drive the development of DGC through distinct biochemical and signaling mechanisms.
Science SignalingBiochemistry, Genetics and Molecular Biology-Molecular Biology
自引率
0.00%
发文量
148
期刊介绍:
Science Signaling is a weekly, online multidisciplinary journal dedicated to the life sciences. Our editorial team's mission is to publish studies that elucidate the fundamental mechanisms underlying biological processes across various organisms. We prioritize research that offers novel insights into physiology, elucidates aberrant mechanisms leading to disease, identifies potential therapeutic targets and strategies, and characterizes the effects of drugs both in vitro and in vivo.